The full content of Annals is available to subscribers

Subscribe/Learn More  >
Reviews |

Medical Treatment for Stroke Prevention

David B. Matchar, MD; Douglas C. McCrory, MD; Henry J. M. Barnett, MD; and John R. Feussner, MD
[+] Article, Author, and Disclosure Information

From Duke University and Durham Veterans Affairs Medical Center, Durham, North Carolina; the University of Western Ontario, London, Ontario, Canada. Requests for Reprints: David B. Matchar, MD, Center for Health Policy Research and Education, Duke University, P.O. Box 90253, Durham, NC 27708. Acknowledgments: The authors thank Vic Hasselblad, PhD, John Pauk, MD, Pam Duncan, PhD, Greg Samsa, PhD, Emilia Richichi, PhD, Fikri Yucel, and Samantha Mackey for technical assistance; Annette Jurgelski for editorial assistance; and Kathy Malone and Sandy Thomas for manuscript preparation.

Copyright ©2004 by the American College of Physicians

Ann Intern Med. 1994;121(1):41-53. doi:10.7326/0003-4819-121-1-199407010-00008
Text Size: A A A

Purpose: To review the effectiveness of medical treatments for stroke prevention in patients at elevated risk for stroke.

Data Sources: English-language articles published after 1977 and indexed in MEDLINE under the following Medical Subject Heading terms: anticoagulants, aspirin, dipyridamole, ticlopidine, or sulfinpyrazone, combined with cerebrovascular disorders.

Study Selection: Randomized controlled trials of anticoagulant or platelet antiaggregant treatment reporting subsequent stroke and myocardial infarction, death, or complications in persons with asymptomatic carotid stenosis or bruit, transient ischemic attack (TIA), previous stroke, nonvalvular atrial fibrillation, or other vascular diseases.

Data Extraction: Of 900 articles identified, 33 were selected by two independent reviewers and abstracted for outcome events and person-years of follow-up.

Results: In patients with nonvalvular atrial fibrillation, warfarin is highly effective in reducing stroke and death but may result in more complications. Aspirin appears to be less effective and less risky than anticoagulation. In patients with TIA or minor stroke, both aspirin and ticlopidine reduce the risk for stroke. In patients who have had myocardial infarction, warfarin is effective but had high complication rates in the reviewed studies. Aspirin slightly reduces the risk for stroke.

Conclusions: Warfarin is strongly recommended for persons with nonvalvular atrial fibrillation who are older than 60 years or who have additional risk factors for stroke. Aspirin is recommended for persons at elevated risk for bleeding while receiving anticoagulants. For persons with TIA or minor stroke, aspirin should be used first. Patients who do not respond to or tolerate aspirin or who have had a major stroke are reasonable candidates for ticlopidine. For patients who have had myocardial infarction, aspirin is recommended for the prevention of secondary myocardial infarction but not of stroke.


Grahic Jump Location
Figure 1.
The relative risk for stroke estimated from eight randomized, controlled trials of aspirin as compared with placebo, plotted against the target aspirin dose in that trial.
Grahic Jump Location




Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).


Submit a Comment/Letter
Submit a Comment/Letter

Summary for Patients

Clinical Slide Sets

Terms of Use

The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.


Buy Now for $32.00

to gain full access to the content and tools.

Want to Subscribe?

Learn more about subscription options

Related Articles
Related Point of Care
Topic Collections
PubMed Articles
Forgot your password?
Enter your username and email address. We'll send you a reminder to the email address on record.